Company Filing History:
Years Active: 2021-2025
Title: Innovator Robert Frank Roscigno: Pioneering Treatments for Pulmonary Hypertension
Introduction: Robert Frank Roscigno, a prominent inventor based in Melbourne Beach, Florida, has made significant contributions to the field of pharmaceutical innovations. With an impressive portfolio of six patents, Roscigno's work primarily focuses on developing novel treatments for pulmonary hypertension.
Latest Patents: Among his latest innovations is the patent for "Dry powder treprostinil for the treatment of pulmonary hypertension." This groundbreaking invention presents a dry powder inhalation therapy for pulmonary arterial hypertension, which includes a dose of dry particles comprising more than 25 micrograms of treprostinil, securely enclosed in a capsule. The formulation emphasizes the integration of various agents, such as a wetting agent, a hydrophobicity modifying agent, a pH modifying agent, and a buffer. The method aims to enhance the patient experience by providing a dry powder inhaler along with capsules containing treprostinil for effective treatment.
Career Highlights: Roscigno's career is marked by his association with leading companies in the pharmaceutical sector, including Liquidia Technologies, Inc. and Vero Biotech Inc. His dedication to improving pulmonary hypertension treatments has garnered attention within the scientific community.
Collaborations: Throughout his career, Roscigno has collaborated with esteemed colleagues, including Brian T. Farrer and Jacob J. Sprague. These partnerships highlight his commitment to advancing medical solutions through teamwork and shared expertise.
Conclusion: Robert Frank Roscigno's innovative spirit and dedication to healthcare continue to drive him forward in his endeavors. With a strong foundation of patents and collaborative work, Roscigno remains a vital figure in the development of effective treatments for pulmonary hypertension, promising better health outcomes for patients in need.